NICE treats the three CDK4/6 inhibitors as mutually appropriate comparators for each other, but no trial has ever run any of them head-to-head against exemestane plus everolimus, the regimen they displaced.
NICE's technology appraisals for the CDK4/6 inhibitor class in HR+/HER2- advanced breast cancer, TA836 for palbociclib plus fulvestrant, TA725 for abemaciclib plus fulvestrant, and TA687 for ribociclib plus fulvestrant, all treat the class as internally comparable. The committee concluded that abemaciclib plus fulvestrant and ribociclib plus fulvestrant are appropriate comparators for palbociclib plus fulvestrant, drawing on pivotal trials including MONARCH 2 (n=669, abemaciclib) and MONALEESA-3 (n=726, ribociclib). The three drugs share a mechanism but differ in dosing. Palbociclib and ribociclib are once-daily for 21 of a 28-day cycle, while abemaciclib is twice-daily continuously, a PICO-relevant distinction that shapes tolerability comparisons.
The comparator framework has a real gap outside the class itself. No trial directly compares ribociclib plus fulvestrant, or either of its class-mates, against exemestane plus everolimus, the endocrine-based regimen that was standard of care before CDK4/6 inhibitors arrived. That absence matters for any new entrant's HTA submission. NICE's within-class comparator acceptance does not extend automatically to a comparator outside the class, and a submission that assumes it does risks exactly the kind of committee pushback that HEOR teams should price in before the dossier is finalised. Our gap register scores this specific comparator absence by likelihood of being raised and impact if it is, rather than treating every appraisal's evidence base as equally solid.
UK CDK4/6 inhibitor comparator landscape — within-class precedent, and the gap outside it
| Agent | NICE TA | Pivotal Trial | Within-Class Comparator Status |
|---|---|---|---|
| Palbociclib + fulvestrant | TA836 | PALOMA-3 | Reference comparator for the class |
| Abemaciclib + fulvestrant | TA725 | MONARCH 2 (n=669) | Accepted as comparator to palbociclib |
| Ribociclib + fulvestrant | TA687 | MONALEESA-3 (n=726) | Accepted as comparator to palbociclib; no head-to-head vs. exemestane plus everolimus |
Sources: NICE TA836 (palbociclib plus fulvestrant), Committee Discussion; NICE TA725 (abemaciclib plus fulvestrant), Committee Discussion; NICE TA687 (ribociclib plus fulvestrant), Committee Discussion.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NICE's TA836/TA725/TA687 comparator-acceptance precedent
- the absent head-to-head evidence against exemestane plus everolimus
- the HEOR risk this creates for a new submission
Delivers
- Once-daily 21/28 (palbociclib, ribociclib) versus continuous twice-daily (abemaciclib) dosing
- tolerability-comparison implications
- PICO framework construction methodology
Delivers
- Likelihood-times-impact scoring methodology
- submission-blocking versus manageable gap classification
- the 9-sheet HTA Strategy Model structure
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the missing exemestane-plus-everolimus comparator, not the within-class evidence, is the single gap that determines whether the dossier survives challenge
- Pressure-tested against the TA836/TA725/TA687 precedent before the rest of the model is built out
- NICE's technology appraisal process for the CDK4/6 class
- How TA836, TA725, and TA687 relate to each other as precedent
- Population, Intervention, Comparator, Outcomes built to NICE's requirements
- Dosing-schedule differences (once-daily 21/28 vs. continuous twice-daily) as a PICO-relevant distinction
- The 3-test comparator defence framework applied to a new CDK4/6-class entrant
- The exemestane-plus-everolimus gap and why it falls outside NICE's within-class precedent
- 5-module, 15-check self-assessment against submission readiness
- Where the dossier is exposed on the exemestane-plus-everolimus question
- The comparator gap scored by likelihood of being raised and impact if it is
- Submission-blocking versus manageable classification
- Economic model type selection and benchmark utility values for this class
- Milestone timeline against NICE's appraisal process
- The open HEOR questions your team must close before the dossier is finalised
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx HTA strategy model is built from primary HTA-body sources (NICE technology appraisals and committee discussions), not secondary summaries. Every comparator claim is pressure-tested through the 3-test defence framework before being accepted.
UK HR+/HER2- mBC HTA sources: NICE TA836 (palbociclib plus fulvestrant), TA725 (abemaciclib plus fulvestrant), and TA687 (ribociclib plus fulvestrant) committee discussion documents.
- NICE TA836, TA725, and TA687 committee conclusions on within-class comparator acceptance verified against the live NICE guidance pages
- Absence of head-to-head trial evidence against exemestane plus everolimus verified via direct search of the same committee discussion documents
- MONARCH 2 and MONALEESA-3 patient counts verified against the same NICE committee discussion documents
Frequently asked questions
Commission this model
AXLRx delivers oncology HTA strategy models built for market access and HEOR teams navigating NICE comparator precedent and evidence gaps. Custom model in 72 hours.
Specify your indication, HTA bodies, and comparator scope.
AXLRx analyst confirms comparator set and evidence-gap scope before building.
Research-verified HTA strategy model in 72 hours with optional analyst readout.